Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | CASR | P41180 | 2/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.61 |
| ▸ | DRD1 | P21728 | 1/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9019451 | 1.00 | CYP3A4 (0.61) | CYP3A4CASRCHRM2HTR1AADRA2A | |
| SCHEMBL8366747 | 1.00 | CYP3A4 (0.61) | CYP3A4CASRCHRM2HTR1AADRA2A | |
| SCHEMBL3881699 | 0.83 | CYP3A4 (0.76) | CYP3A4CASRCHRM2HTR1AADRA2A | |
| SCHEMBL3881700 | 0.83 | CYP3A4 (0.76) | CYP3A4CASRCHRM2HTR1AADRA2A | |
| SCHEMBL5471668 | 0.83 | CYP3A4 (0.76) | CYP3A4CASRCHRM2HTR1AADRA2A | |
| SCHEMBL24406703 | 0.83 | CYP3A4 (0.76) | CYP3A4CASRCHRM2HTR1AADRA2A | |
| SCHEMBL12747746 | 0.82 | ACACB (0.53) | CYP3A4CASRCHRM2HTR1AADRA2A | |
| SCHEMBL12964248 | 0.82 | CYP3A4 (0.68) | CYP3A4CASRCHRM2HTR1AADRA2A | |
| SCHEMBL12964253 | 0.82 | CYP3A4 (0.68) | CYP3A4CASRCHRM2HTR1AADRA2A | |
| SCHEMBL172559 | 0.82 | CYP3A4 (0.68) | CYP3A4CASRCHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112500429-B | Preparation method of Reidesciclovir intermediate | 东南大学 | 2022-04-12 | — | — | CN | claimed |
| CN-112500429-A | Preparation method of Reidesciclovir intermediate | 东南大学 | 2021-03-16 | — | — | CN | claimed |
| EP-2552891-A1 | TRICYCLIC INDOLE DERIVATIVES AS PBR LIGANDS | GE Healthcare Limited (GB) | 2013-02-06 | — | — | EP | claimed |
| WO-2011117421-A1 | TRICYCLIC INDOLE DERIVATIVES AS PBR LIGANDS | GE HEALTHCARE LIMITED (GB) | 2011-09-29 | — | — | WO | claimed |
| US-20110070161-A1 | ACTIVE ENANTIOMER | GE HEALTHCARE LIMITED (GB) | 2011-03-24 | — | — | US | claimed |
| US-20250136552-A1 | ANTAGONISTS OF CAV 2.3 | LARIO THERAPEUTICS LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| EP-4436664-A1 | ANTAGONISTS OF CAV 2.3 | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| CN-117327050-A | Bimetal synergistic promotion system and application thereof in asymmetric synthesis of (S, S) -TBAJ-587 | 上海交通大学 | 2024-01-02 | — | — | CN | disclosed |
| WO-2023094828-A1 | ANTAGONISTS OF CAV 2.3 | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| EP-4032884-A1 | CRYSTAL OF 1,3,5-TRIAZINE DERIVATIVE OR SOLVATE THEREOF AND METHOD FOR PRODUCING SAME | Shionogi & Co., Ltd. (JP) | 2022-07-27 | — | — | EP | disclosed |
| US-20220135561-A1 | IMIDAZOPYRIDINE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-05-05 | — | — | US | disclosed |
| CN-112500429-B | Preparation method of Reidesciclovir intermediate | 东南大学 | 2022-04-12 | — | — | CN | disclosed |
| US-5436240-A | Schizophrenia, Parkinson's disease, depression or hypotensive agents using tricyclic amines | THE UPJOHN COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| WO-1995016674-A1 | AMINOSULPHONYL-PHENYL-1H-PYRROLE DERIVATIVES, METHOD OF THEIR PREPARATION AND THEIR USE | SMITHKLINE BEECHAM PLC (GB) | 1995-06-22 | — | — | WO | disclosed |
| US-5273975-A | Heterocyclic amines having central nervous system activity | THE UPJOHN COMPANY (US) | 1993-12-28 | — | — | US | disclosed |
| EP-0558656-A1 | NEW METHODS FOR THE CATALYTIC REDUCTION OF ORGANIC SUBSTRATES. | MASSACHUSETTS INST TECHNOLOGY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0514540-A1 | PYRROLO 2,3-d]PYRIMIDINE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL PREPARATION COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 1992-11-25 | — | — | EP | disclosed |
| WO-1992009545-A2 | NEW METHODS FOR THE CATALYTIC REDUCTION OF ORGANIC SUBSTRATES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1992-06-11 | — | — | WO | disclosed |
| US-4958029-A | Process for the production of isoindoline derivatives, novel intermediates and process for their production | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1990-09-18 | — | — | US | disclosed |
| EP-0275064-A2 | Process for the production of isoindoline derivatives, novel intermediates and process for their production | Banyu Pharmaceutical Co., Ltd. (JP) | 1988-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070161-A1 | ACTIVE ENANTIOMER | GABRA5, GABRP, GABRA4 | CYP3A4 132/4885CASR 2805/4885CHRM2 558/4885 |
| US-20220135561-A1 | IMIDAZOPYRIDINE DERIVATIVES | TPMT, IRAK4, CFTR | CYP3A4 48/4885CASR 4225/4885CHRM2 1595/4885 |
| US-20250136552-A1 | ANTAGONISTS OF CAV 2.3 | CACNA1E, CACNA1A, CACNA1S | CYP3A4 2976/4885CASR 190/4885CHRM2 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.